NEW THYROID HORMONE BETA-RECEPTOR AGONIST Russian patent published in 2014 - IPC C07D213/65 C07D213/74 C07D213/75 C07D213/81 C07D401/10 C07D405/04 C07D413/12 C07D413/14 A61K31/44 A61K31/4418 A61K31/443 A61K31/4433 A61K31/4439 A61P1/16 A61P17/00 A61P43/00 A61P5/14 A61P9/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a new compound of formula [I] or to its pharmaceutically acceptable salt, wherein A represents optionally substituted alkyl, wherein the substitute represents identical or different 1-3 groups specified in aryl optionally substituted by 1-3 groups specified in alkyl, halogen, alkoxy and alkanoyl; cycloalkyl optionally substituted by 1-3 groups specified in alkyl and halogen; hydroxy; alkoxy; halogen; an amino group and oxo; an optionally substituted carbocyclic group specified in a mono- and bicyclic group, wherein an aromatic ring and cycloalkyl are condensed; optionally substituted aryl, an optionally substituted completely saturated 5- or 6-merous monocyclic heterocyclic group each of which contains 1 heteroatom specified in nitrogen and oxygen, wherein the substitute of optionally substituted aryl, the optionally substituted carbocyclic group and the optionally substituted heterocyclic group for A represents identical or different 1-3 groups specified in alkyl, optionally substituted hydroxy, alkoxy, cycloalkyl or halogen; cycloalkyl optionally substituted by alkyl or alkoxy; alkoxy optionally substituted by halogen; halogen; hydroxy; oxo; heterocycle; alkyl sulphonyl; and mono- or dialkylcarbamoyl, optionally substituted amino, wherein the substitute represents identical or different 1 or 2 alkyl or aryl, or optionally substituted carbamoyl, wherein the substitute represents identical or different 1 or 2 alkyls optionally substituted by aryl, X represents optionally substituted methylene or -O-, wherein the substitute of optionally substituted methylene for X represents alkoxy or hydroxy, Q represents N or C-R⁴, L¹ represents a single bond, methylene, -CH=CH-, -O-, -CO-, -NR¹¹-, -NR¹¹CO-, -CONR¹¹- or -CH₂NR¹¹-, L² represents a single bond, -CR⁶R⁷- or a bivalent 5- or 6-merous completely saturated monocyclic heterocyclic group each of which contains 1 heteroatom specified in nitrogen and oxygen, R¹ and R² are identical or different, and each represents hydrogen, alkyl or halogen, R³ and R⁴ are identical or different, and each represents hydrogen, alkyl, alkoxy, cyano or halogen, R¹ and R³ are optionally bond thereby forming 5- or 6-merous cycloalkane, or a 5- or 6-merous aliphatic heterocycle containing oxygen atom, R⁵ represents a carboxyl group, an alkoxycarbonyl group or a bioisosteric group of the carboxyl group, R⁶ and R⁷ are identical or different, and each represents hydrogen or alkyl, or R⁶ and R⁷ are bond thereby forming cycloalkane, R⁸ represents hydroxy, alkanoylamino or alkyl sulphonylamino, R⁹ and R¹⁰ represent hydrogen or halogen, and R¹¹ represents hydrogen or alkyl. Besides, the invention refers to specific compounds of formula [I], a drug based on the compound of formula [I], using the compound of formula [I], a method of treating based on using the compound of formula [I], and an intermediate compound of formula [II].

EFFECT: there are prepared new compounds possessing the agonist activity on thyroid hormone β receptor.

18 cl, 36 tbl, 344 ex